@willkidney profile picture
Will Herrington @willkidney

Prof@Oxford_NDPH, Hon.Nephrologist, EMPA-KIDNEY & EASi-KIDNEY CI. Join the fight against CKD, systematic bias & random error: make studies larger & randomized!

Joined April 2016
  • Tweets 667
  • Following 627
  • Followers 1,638
68 Photos and videos
Pinned Tweet
Will Herrington@willkidney
7 Nov 2025
Such a great @NatalieStaplin figure for SMART-C - should be on a #KidneyWk postcard we can buy (or on a souvenir fidget magnet!)
JAMA
@JAMA_current
7 Nov 2025
#SGLT2 inhibitors reduced #KidneyDisease progression, hospitalizations, and mortality in CKD, regardless of #diabetes status or albuminuria level, supporting broader use in clinical guidelines. #KidneyWK @ASNKidney ja.ma/4nGjis4
1
3
21
3,234
10,000 screened up on the same day!
Oxford Population Health (OxPop)@Oxford_NDPH
May 29
🎉EASi-KIDNEY has recruited 6000 randomised participants! 📉EASi-KIDNEY will investigate whether a novel treatment can help slow the progression of chronic kidney disease (CKD) ➡️buff.ly/qXd6j1S
0:05
1
10
628
Will Herrington retweeted
Hans-Joachim Anders@hjanders_hans
Apr 25
Now open access in @NDTsocial UACR and UPCR with kidney failure: a pooled analysis of clinical trials 🧐UACR and UPCR are robust predictors of kidney failure, but UACR has stronger associations, particularly in CKD diabetes. ▶️academic.oup.com/ndt/article…
14
36
1,724
Will Herrington retweeted
Hans-Joachim Anders@hjanders_hans
Apr 16
Now open access in @NDTsocial @ERAkidney ERA’s ABCDE framework for kidney disease prevention: turning the WHO kidney health resolution into action ▶️academic.oup.com/ndt/article…
10
23
2,120
Extraordinarily large effects of #SGLT2i on urinary uromodulin (unexpected & a call to reverse translational science to understand better the mechanisms of renal benefits of SGLT2i). @grecombm @Oxford_NDPH DPhil.
AJKD@AJKDonline
Apr 17
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY bit.ly/3WA9uoy #OpenAccess @grecombm @NatalieStaplin @Dilushiwijay @KillianDonovan @doreen_zhu @kayzieb77 @sarahngyoonai @KatherineTuttl8 @MartinLandray @ChristophWanne4 @shlipak_khrc @willkidney @Oxford_NDPH
5
19
3,111
#EASi-KIDNEY showing how a group of >450 amazingly motivated local clinical sites can surpass EMPA-KIDNEY (n=6609). EASi-KIDNEY has ~4850 randomized pts with #CKD & ~2000 in run-in. This forecasts overtaking EMPA-KIDNEY in late May. Deep gratitude to all from @Oxford_NDPH
2
4
22
1,341
EASi-KIDNEY teams globally just screened 800 pts with #CKD a month on average for 5 months in succession. Mind-blowing commitment! @DCRINews @GeorgeInstIN @TrialsCentre @ChristophWanne4 @_anmco @adeeralevin @OtavioBerwanger @KatherineTuttl8 @P_Rossing @TorBiering @DitteHansen7
3
16
1,018
Will Herrington retweeted
Gunnar Henrik Heine@gunnar_heine
Mar 7
CKD and HF: Conclusions from a KDIGO Controversies Conference Unfortunately submitted before publication of presentation of DIGIT-HF and DECISION 😆 @JBauersachsMD kidney-international.org/art…
1
41
115
7,101
Will Herrington retweeted
ERA - European Renal Association
@ERAkidney
Mar 1
📣SGLT2 inhibition for patients with ADPKD – closing the evidence gap 👉 an @erakidney e-seminar of the ERA Journal Club Speaker: @MuellerRom Moderator: @willkidney , Parminder Judge Panelist: Roslyn Simms
1
16
39
2,052
Error in NDT paper title IMO.😬The key conclusion from JAMA limits relevance to studied pts (ie, opposite of overgeneralisation). Worthy point is the limitation of available RCTs is lack of data on SGLT2i in pts with all of the 5x following: eGFR>45 uACR<200 no DM no HF no ASCVD!
NDT@NDTsocial
Feb 12
🎦Watch Dr Mariana Murea present the NDT publication: Meta-analyses overgeneralize SGLT2 inhibitor effectiveness in populations with low albuminuria, no diabetes, no heart failure and no atherovascular heart disease oup.cloud.panopto.eu/Panopto…
3
11
1,670
Will Herrington retweeted
NEJM
@NEJM
Feb 3
Our latest video in our partnership with @DGlaucomflecken summarizes the POTCAST trial, which assessed a strategy of actively increasing plasma potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias. Read the full study for free: nej.md/DrG35
1:28
32
251
89,730
Will Herrington retweeted
AJKD@AJKDonline
Feb 5
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY bit.ly/3WA9uoy #OpenAccess @grecombm @NatalieStaplin @Dilushiwijay @KillianDonovan @doreen_zhu @kayzieb77 @sarahngyoonai @KatherineTuttl8 @MartinLandray @ChristophWanne4 @shlipak_khrc @willkidney @Oxford_NDPH
13
40
2,208
Will Herrington retweeted
AJKD@AJKDonline
Jan 14
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY bit.ly/3WA9uoy (OPEN ACCESS) @grecombm @NatalieStaplin @Dilushiwijay @KillianDonovan @doreen_zhu @kayzieb77 @sarahngyoonai @KatherineTuttl8 @MartinLandray @ChristophWanne4 @shlipak_khrc
Effect of empagliflozin versus placebo on study average concentration of urine biomarkers (indexed to urine creatinine). The MMRM model was adjusted for the prognostic variables specified in the minimized randomization algorithm (i.e., age, sex, prior diabetes, eGFR, uACR, and trial site region) in the same categories used in the minimization process, initial freezer storage temperature (-20°C versus below -20°C) and baseline log2-transformed urine biomarker-creatinine ratio. A weighted average of 2- and 18- month values proportional to the amount of time between visits was used to estimate the study average log2-transformed urine biomarker-to-creatinine ratio in each arm. Absolute values indicate geometric mean (approximate SE) creatinine-indexed urine biomarker concentration in the units specified. The size of the boxes represents the amount of information estimated.

ALT Effect of empagliflozin versus placebo on study average concentration of urine biomarkers (indexed to urine creatinine). The MMRM model was adjusted for the prognostic variables specified in the minimized randomization algorithm (i.e., age, sex, prior diabetes, eGFR, uACR, and trial site region) in the same categories used in the minimization process, initial freezer storage temperature (-20°C versus below -20°C) and baseline log2-transformed urine biomarker-creatinine ratio. A weighted average of 2- and 18- month values proportional to the amount of time between visits was used to estimate the study average log2-transformed urine biomarker-to-creatinine ratio in each arm. Absolute values indicate geometric mean (approximate SE) creatinine-indexed urine biomarker concentration in the units specified. The size of the boxes represents the amount of information estimated.
7
26
1,741
Will Herrington retweeted
JAMA
@JAMA_current
Jan 20
💬 Editorial: #SGLT2 inhibitor treatment benefits extend to people with CKD and low albuminuria, as well as those with advanced #KidneyDisease, supporting wider use. ja.ma/4r2qv7Z
1
9
46
4,354
Will Herrington retweeted
JAMA
@JAMA_current
Jan 20
Meta-analysis: #SGLT2 inhibitors slow kidney decline consistently across CKD severity and albuminuria range, supporting their routine use for kidney health. ja.ma/3YK8cZ9
Four graphs display events prevented or caused per 1000 patients treated with a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor for 1 Year by Diabetes Status and Level of Albuminuria. The graphs show variance for diabetes vs. no diabetes.

ALT Four graphs display events prevented or caused per 1000 patients treated with a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor for 1 Year by Diabetes Status and Level of Albuminuria. The graphs show variance for diabetes vs. no diabetes.

1
19
48
5,044
Will Herrington retweeted
Dr. Marty Makary
@DrMakaryFDA
Jan 13
FDA is now open to Bayesian statistical approaches. A leap forward! Bayesian statistics can help: ✅ Clinical trial design ✅ Finding the optimal dose ✅ Extrapolation to children ✅ Leveraging phase 2 results in phase 3
1:09
195
413
3,516
652,064
Will Herrington retweeted
Oxford Population Health (OxPop)@Oxford_NDPH
Jan 9
🎉EASi-KIDNEY has recruited 3000 randomised participants! 📉EASi-KIDNEY will investigate whether a novel treatment can help slow the progression of chronic kidney disease (CKD) ➡️buff.ly/qXd6j1S
Oxford Population Health. EASi-KIDNEY 3000 participants recruited.

ALT Oxford Population Health. EASi-KIDNEY 3000 participants recruited.
2
4
412
Will Herrington retweeted
Nephrology Journal Club@NephJC
Jan 7
18/ #NephJC EMPA individual-level meta by @willkidney , pooled data from >23,000 patients across four empagliflozin trials showed consistent reductions in AKI, CKD progression, and kidney failure across all subgroups PMID: 41082889 nephjc.com/news/2025/10/20/e…
1
10
19
993
Will Herrington retweeted
Gunnar Henrik Heine@gunnar_heine
Jan 3
Replying to @TheLancet
@TheLancet starts the academic year with a landmark review on CKD with four global leaders @willkidney Parminder K Judge @meg21212 @ChristophWanne4 thelancet.com/journals/lance… @MarkusAtHome
24
64
4,459
#EASi-KIDNEY’s December logo🎄🎅 . ‘Tis the season to be jolly!! ⁦@Oxford_NDPH⁩
2
14
858
Fascinating Effects of Empagliflozin on UMOD in EMPA-KIDNEY - American Journal of Kidney Diseases - discussed ⁦@TwSocNephrolTSN⁩ yesterday #APCNxTSN25 ⁦@grecombm⁩ DPhil ajkd.org/article/S0272-6386(…

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY

Sodium/glucose cotransporter 2 (SGLT2) inhibitors substantially slow progression of chronic kidney disease and reduce the risk of acute kidney injury, but their effects on kidney physiology are...

ajkd.org
1
12
28
3,049
Load more